Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
暂无分享,去创建一个
Jeffrey A Lieberman | Gary G Koch | Robert A Rosenheck | J. Lieberman | G. Koch | S. Davis | R. Rosenheck | T. Stroup | C. E. Davis | Sonia M Davis | T Scott Stroup | Clarence E Davis
[1] Lisa M LaVange,et al. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. , 2003, Schizophrenia bulletin.
[2] A. Herring,et al. A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time‐to‐event methods that jointly incorporate information from longitudinal and time‐to‐event data , 2009, Statistics in medicine.
[3] Per Capita,et al. About the authors , 1995, Machine Vision and Applications.
[4] Yu Cheng,et al. Nonparametric Association Analysis of Bivariate Competing-Risks Data , 2007 .
[5] R. Little. Pattern-Mixture Models for Multivariate Incomplete Data , 1993 .
[6] M. Wulfsohn,et al. A joint model for survival and longitudinal data measured with error. , 1997, Biometrics.
[7] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[8] Alexander L. Miller,et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. , 2007, The American journal of psychiatry.
[9] Robert O'Neill,et al. MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets , 2009, Journal of biopharmaceutical statistics.
[10] Limin Peng,et al. Regression Modeling of Semicompeting Risks Data , 2007, Biometrics.
[11] R. Rosenheck,et al. Joint modelling of longitudinal outcome and interval‐censored competing risk dropout in a schizophrenia clinical trial , 2012, Journal of the Royal Statistical Society. Series A,.
[12] N M Laird,et al. Mixture models for the joint distribution of repeated measures and event times. , 1997, Statistics in medicine.
[13] R Henderson,et al. Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.
[14] D.,et al. Regression Models and Life-Tables , 2022 .
[15] J. Lieberman,et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic , 2006 .
[16] J. Lieberman,et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.
[17] P. Allison. Survival analysis using the SAS system : a practical guide , 1995 .
[18] W T Carpenter,et al. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.
[19] Helena Chmura Kraemer,et al. Clinical trials design lessons from the CATIE study. , 2009, The American journal of psychiatry.